Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2006 | 12-2005 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 4,027 | N/A | N/A |
| Marketable Securities | 26,881 | N/A | N/A |
| TOTAL | $31,540 | $N/A | $N/A |
| Non-Current Assets | |||
| PPE Net | 27 | N/A | N/A |
| Investments And Advances | 10,420 | 0 | 0 |
| Other Non-Current Assets | 66 | 0 | 0 |
| TOTAL | $10,513 | $N/A | $N/A |
| Total Assets | $42,053 | $N/A | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 1,526 | 0 | 0 |
| Accrued Expenses | 581 | N/A | N/A |
| TOTAL | $3,903 | $N/A | $N/A |
| Non-Current Liabilities | |||
| Deferred Revenues | 1,796 | N/A | N/A |
| Other Non-Current Liabilities | 57 | 0 | 0 |
| TOTAL | $8,588 | $N/A | $N/A |
| Total Liabilities | $12,491 | $N/A | $N/A |
| Shareholders' Equity | |||
| Common Shares | 1 | N/A | N/A |
| Retained earnings | -30,115 | N/A | N/A |
| Other shareholders' equity | 58,977 | 0 | 0 |
| TOTAL | $29,562 | $N/A | $N/A |
| Total Liabilities And Equity | $42,053 | $0 | $0 |